Atlas Trials

CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer

Clinical trial NCT05029999 · RECRUITING

Trial details

NCT number
NCT05029999
Sponsor
University of Texas Southwestern Medical Center
Status
RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
HER2-negative Breast CancerMetastatic Breast Cancer
Start date
2022-04-20
Primary completion
2028-04-20
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.